|
1
|
Vieira E, Silva FF, Caponio VCA, Ballini A, Chamorro-Petronacci CM, Lourenzo-Pouso AI, García-García A, Di Domenico M, Suaréz-Peñaranda JM, Pérez-Sayáns M and Padín-Iruegas ME: Smac/DIABLO protein acts as an independent prognostic factor in oral squamous cell carcinoma. Sci Rep. 14:300652024. View Article : Google Scholar
|
|
2
|
Silva FFVE, Caponio VCA, Pérez-Sayáns M, Padín-Iruegas ME, Mascitti M, Chamorro-Petronacci CM, Suaréz-Peñaranda JM and Lorenzo-Pouso AI: Tumor budding is a prognostic factor in head and neck squamous cell carcinoma: A comprehensive meta-analysis and trial sequential analysis. Crit Rev Oncol Hematol. 193:1042022024. View Article : Google Scholar
|
|
3
|
Kim E, Chung M, Jeong HS, Baek CH and Cho J: Histological features of differentiated dysplasia in the oral mucosa: A review of oral invasive squamous cell carcinoma cases diagnosed with benign or low-grade dysplasia on previous biopsies. Hum Pathol. 126:45–54. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Almangush A, Leivo I and Mäkitie AA: Biomarkers for immunotherapy of oral squamous cell carcinoma: Current status and challenges. Front Oncol. 11:6166292021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs working group 2014. Ann Oncol. 26:259–271. 2015. View Article : Google Scholar
|
|
6
|
Wu B, Luo D, Wang X, Qiao C, Li R and Liu J: The global trends and distribution in tumor-infiltrating lymphocytes over the past 49 years: bibliometric and visualized analysis. Front Immunol. 15:15118662025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Torri M, Sandell A and Al-Samadi A: The prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Biomed Pharmacother. 180:1175442024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eberlein TJ, Rosenstein M and Rosenberg SA: Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 156:385–397. 1982.PubMed/NCBI
|
|
9
|
Troiano G, Rubini C, Togni L, Caponio VCA, Zhurakivska K, Santarelli A, Cirillo N, Lo Muzio L and Mascitti M: The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis. Cancer Med. 9:8333–8344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boxberg M, Leising L, Steiger K, Jesinghaus M, Alkhamas A, Mielke M, Pfarr N, Götz C, Wolff KD, Weichert W and Kolk A: Composition and clinical impact of the immunologic tumor microenvironment in oral squamous cell carcinoma. J Immunol. 202:278–291. 2019. View Article : Google Scholar
|
|
11
|
Wongpattaraworakul W, Choi A, Buchakjian MR, Lanzel EA, Kd AR and Simons AL: Prognostic role of tumor-infiltrating lymphocytes in oral squamous cell carcinoma. BMC Cancer. 24:7662024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quan H, Shan Z, Liu Z, Liu S, Yang L, Fang X, Li K, Wang B, Deng Z, Hu Y, et al: The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction. Cancer Immunol Immunother. 69:465–476. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang Z, Xie N, Liu H, Wan Y, Zhu Y, Zhang M, Tao Y, Zhou H, Liu X, Hou J and Wang C: The prognostic role of tumour-infiltrating lymphocytes in oral squamous cell carcinoma: A meta-analysis. J Oral Pathol Med. 48:788–798. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ni YH, Zhang XX, Lu ZY, Huang XF, Wang ZY, Yang Y, Dong YC, Jing Y, Song Y, Hou YY, et al: Tumor-infiltrating CD1a+ DCs and CD8+/FoxP3+ ratios served as predictors for clinical outcomes in tongue squamous cell carcinoma patients. Pathol Oncol Res. 26:1687–1695. 2020. View Article : Google Scholar
|
|
15
|
Chen WY, Wu CT, Wang CW, Lan KH, Liang HK, Huang BS, Chang YL, Kuo SH and Cheng AL: Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer. Radiat Oncol. 13:1572018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ and Kodumudi K: Differentiation and regulation of TH cells: A balancing act for cancer immunotherapy. Front Immunol. 12:6694742021. View Article : Google Scholar
|
|
17
|
Starska-Kowarska K: The role of different immunocompetent cell populations in the pathogenesis of head and neck cancer-regulatory mechanisms of pro- and anti-cancer activity and their impact on immunotherapy. Cancers (Basel). 15:16422023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayashi T, Yoshikawa K, Suzuki S, Gosho M, Ueda R and Kazaoka Y: Tumor-infiltrating FoxP3+ T cells are associated with poor prognosis in oral squamous cell carcinoma. Clin Exp Dent Res. 8:152–159. 2022. View Article : Google Scholar :
|
|
19
|
Song JJ, Zhao SJ, Fang J, Ma D, Liu XQ, Chen XB, Wang Y, Cheng B and Wang Z: Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma. BMC Cancer. 16:5302016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wondergem NE, Nauta IH, Muijlwijk T, Leemans CR and van de Ven R: The immune microenvironment in head and neck squamous cell carcinoma: on subsets and subsites. Curr Oncol Rep. 22:812020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Ruiter EJ, Ooft ML, Devriese LA and Willems SM: The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 6:e13561482017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fiedler M, Off A, Eichberger J, Spoerl S, Schuderer JG, Taxis J, Bauer RJ, Schreml S, Reichert TE, Ettl T and Weber F: OSCC in never-smokers and never-drinkers is associated with increased expression of tumor-infiltrating lymphocytes and better survival. Cancers (Basel). 15:26882023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chao JL, Korzinkin M, Zhavoronkov A, Ozerov IV, Walker MT, Higgins K, Lingen MW, Izumchenko E and Savage PA: Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. Cell Rep Med. 2:1003992021. View Article : Google Scholar
|
|
24
|
Lu Y, Xiang Z, Wang W, Yun B, Yi C, Zhang M, Xie N, Wang C and Zhuang Z: Establishment and validation of a tumor-infiltrating γδT cell related prognostic gene signature in head and neck squamous cell carcinoma. Int Immunopharmacol. 132:1120542024. View Article : Google Scholar
|
|
25
|
Lequerica-Fernández P, Suárez-Canto J, Rodriguez-Santamarta T, Rodrigo JP, Suárez-Sánchez FJ, Blanco-Lorenzo V, Domínguez-Iglesias F, García-Pedrero JM and de Vicente JC: Prognostic relevance of CD4+, CD8+ and FOXP3+ TILs in oral squamous cell carcinoma and correlations with PD-L1 and cancer stem cell markers. Biomedicines. 9:6532021. View Article : Google Scholar
|
|
26
|
Kujan O, Agag M, Smaga M, Vaishnaw Y, Idrees M, Shearston K and Farah CS: PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma. Pathology. 54:409–416. 2022. View Article : Google Scholar
|
|
27
|
Caponio VCA, Zhurakivska K, Lo Muzio L, Troiano G and Cirillo N: The immune cells in the development of oral squamous cell carcinoma. Cancers (Basel). 15:37792023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
John S, Joseph AP, Raghavan Pillai VB, Ramani P, P J and Ramalingam K: Evaluation of cytotoxic T lymphocytes and natural killer cell distribution in oral squamous cell carcinoma and oral epithelial dysplasia: An immunohistochemical study. Cureus. 16:e563232024.PubMed/NCBI
|
|
29
|
Thomas A, Smitha T, Rao K, Priya NS, Sheethal HS and Chitra S: Expression of CD 20 B-lymphocyte in oral epithelial dysplasia and oral squamous cell carcinoma: A comparative immunohistochemistry study. J Oral Maxillofac Pathol. 27:323–327. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Caruntu A, Moraru L, Lupu M, Vasilescu F, Dumitrescu M, Cioplea M, Popp C, Dragusin A, Caruntu C and Zurac S: Prognostic potential of tumor-infiltrating immune cells in resectable oral squamous cell carcinoma. Cancers (Basel). 13:22682021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kumar S, Chandra A, Agrawal R, Singh P and Pallavi M: Prognostic implications of CD-57 expression in oral squamous cell carcinoma cases. Indian J Pathol Microbiol. 66:815–818. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie W, Lu J, Chen Y, Wang X, Lu H, Li Q, Jin N, He J, Ou L, Ni J, et al: TCL1A-expressing B cells are critical for tertiary lymphoid structure formation and the prognosis of oral squamous cell carcinoma. J Transl Med. 22:4772024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sales de Sá R, Miranda Galvis M, Mariz BALA, Leite AA, Schultz L, Almeida OP, Santos-Silva AR, Pinto CAL, Vargas PA, Gollob KJ and Kowalski LP: Increased tumor immune microenvironment CD3+ and CD20+ lymphocytes predict a better prognosis in oral tongue squamous cell carcinoma. Front Cell Dev Biol. 8:6221612021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suárez-Sánchez FJ, Lequerica-Fernández P, Rodrigo JP, Hermida-Prado F, Suárez-Canto J, Rodríguez-Santamarta T, Domínguez-Iglesias F, García-Pedrero JM and de Vicente JC: Tumor-infiltrating CD20+ B lymphocytes: Significance and prognostic implications in oral cancer microenvironment. Cancers (Basel). 13:3952021. View Article : Google Scholar
|
|
35
|
Liu Z, Meng X, Tang X, Zou W and He Y: Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. Cancer Immunol Immunother. 72:1505–1521. 2023. View Article : Google Scholar :
|
|
36
|
Li Q, Liu X, Wang D, Wang Y, Lu H, Wen S, Fang J, Cheng B and Wang Z: Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. Int J Oral Sci. 12:242020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kågedal Å, Hjalmarsson E, Farrajota Neves da Silva P, Piersiala K, Georén SK, Margolin G, Munck-Wikland E, Winqvist O, Häyry V and Cardell LO: Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. Sci Rep. 10:223522020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Piersiala K, Hjalmarsson E, Lagebro V, Farrajota Neves da Silva P, Bark R, Elliot A, Marklund L, Margolin G, Georén SK and Cardell LO: Prognostic value of T regulatory cells and immune checkpoints expression in tumor-draining lymph nodes for oral squamous cell carcinoma. Front Immunol. 15:14554262024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Verginelli F, Pisacane A, Gambardella G, D'Ambrosio A, Candiello E, Ferrio M, Panero M, Casorzo L, Benvenuti S, Cascardi E, et al: Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nat Commun. 12:24982021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pisacane A, Cascardi E, Berrino E, Polidori A, Sarotto I, Casorzo L, Panero M, Boccaccio C, Verginelli F, Benvenuti S, et al: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs). Virchows Arch. 482:463–475. 2023. View Article : Google Scholar
|
|
41
|
Takeya M and Komohara Y: Role of tumor-associated macrophages in human malignancies: Friend or foe? Pathol Int. 66:491–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shigeoka M, Koma YI, Nishio M, Akashi M and Yokozaki H: Alteration of macrophage infiltrating compartment: A novel view on oral carcinogenesis. Pathobiology. 88:327–337. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou WH, Wang Y, Yan C, Du WD, Al-Aroomi MA, Zheng L, Lin SF, Gao JX, Jiang S, Wang ZX, et al: CC chemokine receptor 7 promotes macrophage recruitment and induces M2-polarization through CC chemokine ligand 19&21 in oral squamous cell carcinoma. Discov Oncol. 13:672022. View Article : Google Scholar
|
|
44
|
Kai K, Moriyama M, Haque ASMR, Hattori T, Chinju A, Hu C, Kubota K, Miyahara Y, Kakizoe-Ishiguro N, Kawano S and Nakamura S: Oral squamous cell carcinoma contributes to differentiation of monocyte-derived tumor-associated macrophages via PAI-1 and IL-8 production. Int J Mol Sci. 22:94752021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pang X, Wang SS, Zhang M, Jiang J, Fan HY, Wu JS, Wang HF, Liang XH and Tang YL: OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother. 70:1015–1029. 2021. View Article : Google Scholar
|
|
46
|
Kalogirou EM, Tosios KI and Christopoulos PF: The role of macrophages in oral squamous cell carcinoma. Front Oncol. 11:6111152021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Haque ASMR, Moriyama M, Kubota K, Ishiguro N, Sakamoto M, Chinju A, Mochizuki K, Sakamoto T, Kaneko N, Munemura R, et al: CD206+ tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production. Sci Rep. 9:146112019. View Article : Google Scholar
|
|
48
|
Li J, Bao Y, Peng S, Jiang C, Zhu L, Zou S, Xu J and Li Y: M2 macrophages-derived exosomal miRNA-23a-3p promotes the progression of oral squamous cell carcinoma by targeting PTEN. Curr Issues Mol Biol. 45:4936–4947. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yan Q, Liu J, Liu Y, Wen Z, Jin D, Wang F and Gao L: Tumor-associated macrophage-derived exosomal miR21-5p promotes tumor angiogenesis by regulating YAP1/HIF-1α axis in head and neck squamous cell carcinoma. Cell Mol Life Sci. 81:1792024. View Article : Google Scholar
|
|
50
|
Yamagata Y, Tomioka H, Sakamoto K, Sato K, Harada H, Ikeda T and Kayamori K: CD163-positive macrophages within the tumor stroma are associated with lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma. J Oral Maxillofac Surg. 75:2144–2153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dong L, Hu S, Li X, Pei S, Jin L, Zhang L, Chen X, Min A and Yin M: SPP1+ TAM regulates the metastatic colonization of CXCR4+ metastasis-associated tumor cells by remodeling the lymph node microenvironment. Adv Sci (Weinh). 11:e24005242024. View Article : Google Scholar
|
|
52
|
Nie F, Zhang J, Tian H, Zhao J, Gong P, Wang H, Wang S, Yang P and Yang C: The role of CXCL2-mediated crosstalk between tumor cells and macrophages in Fusobacterium nucleatum-promoted oral squamous cell carcinoma progression. Cell Death Dis. 15:2772024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Weber M, Wehrhan F, Baran C, Agaimy A, Büttner-Herold M, Öztürk H, Neubauer K, Wickenhauser C, Kesting M and Ries J: Malignant transformation of oral leukoplakia is associated with macrophage polarization. J Transl Med. 18:112020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhu Y, Zhang S, Sun J, Wang T, Liu Q, Wu G, Qian Y, Yang W, Wang Y and Wang W: Cigarette smoke promotes oral leukoplakia via regulating glutamine metabolism and M2 polarization of macrophage. Int J Oral Sci. 13:252021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fu E, Liu T, Yu S, Chen X, Song L, Lou H, Ma F, Zhang S, Hussain S, Guo J, et al: M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF. Oncol Rep. 44:698–710. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tomita R, Sasabe E, Tomomura A and Yamamoto T: Macrophage-derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK-3β pathway. Oncol Rep. 44:1905–1916. 2020.PubMed/NCBI
|
|
57
|
Chohan MH, Perry M, Laurance-Young P, Salih VM and Foey AD: Prognostic role of CD68+ and CD163+ tumour-associated macrophages and PD-L1 expression in oral squamous cell carcinoma: A meta-analysis. Br J Biomed Sci. 80:110652023. View Article : Google Scholar
|
|
58
|
Alves AM, Diel LF and Lamers ML: Macrophages and prognosis of oral squamous cell carcinoma: A systematic review. J Oral Pathol Med. 47:460–467. 2018. View Article : Google Scholar
|
|
59
|
Masucci MT, Minopoli M and Carriero MV: Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 9:11462019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Piccard H, Muschel RJ and Opdenakker G: On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol. 82:296–309. 2012. View Article : Google Scholar
|
|
61
|
Fridlender ZG and Albelda SM: Tumor-associated neutrophils: Friend or foe? Carcinogenesis. 33:949–955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, Damti P, Lumbroso D, Polyansky L, Sionov RV, et al: Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 10:562–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hu X, Xiang F, Feng Y, Gao F, Ge S, Wang C, Zhang X and Wang N: Neutrophils promote tumor progression in oral squamous cell carcinoma by regulating EMT and JAK2/STAT3 signaling through chemerin. Front Oncol. 12:8120442022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yu T, Tang Q, Chen X, Fan W, Zhou Z, Huang W and Liang F: TGF-β1 and IL-17A comediate the protumor phenotype of neutrophils to regulate the epithelial-mesenchymal transition in oral squamous cell carcinoma. J Oral Pathol Med. 50:353–361. 2021. View Article : Google Scholar
|
|
65
|
Garley M: Unobvious neutrophil extracellular traps signification in the course of oral squamous cell carcinoma: Current understanding and future perspectives. Cancer Control. 30:107327482311593132023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Garley M, Dziemiańczyk-Pakieła D, Grubczak K, Surażyński A, Dąbrowska D, Ratajczak-Wrona W, Sawicka-Powierza J, Borys J, Moniuszko M, Pałka JA and Jabłońska E: Differences and similarities in the phenomenon of NETs formation in oral inflammation and in oral squamous cell carcinoma. J Cancer. 9:1958–1965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Garley M, Dziemiańczyk-Pakieła D, Ratajczak-Wrona W, Pryczynicz A, Nowak K, Łazarczyk B and Jabłońska E: NETs biomarkers in saliva and serum OSCC patients: One hypothesis, two conclusions. Adv Med Sci. 67:45–54. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhai R, Gong Z, Wang M, Ni Z, Zhang J, Wang M, Zhang Y, Zeng F, Gu Z, Chen X, et al: Neutrophil extracellular traps promote invasion and metastasis via NLRP3-mediated oral squamous cell carcinoma pyroptosis inhibition. Cell Death Discov. 10:2142024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhou J, Hu Z, Wang L, Hu Q, Chen Z, Lin T, Zhou R, Cai Y, Wu Z, Zhang Z, et al: Tumor-colonized Streptococcus mutans metabolically reprograms tumor microenvironment and promotes oral squamous cell carcinoma. Microbiome. 12:1932024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Li C, Zhao L, Wang Q, Ma S, Sun J, Ma C, Liu J, Jing X, Ai D, Nan Z and Qu X: Neutrophils infiltration and its correlation with human papillomavirus status in the oral squamous cell carcinoma. Cancer Manag Res. 11:5171–5185. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Phulari RGS, Rathore RS, Shah AK and Agnani SS: Neutrophil: Lymphocyte ratio and oral squamous cell carcinoma: A preliminary study. J Oral Maxillofac Pathol. 23:78–81. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mishra V, Giri R, Hota S, Senapati U and Sahu SK: Neutrophil-to-lymphocyte ratio as a prognostic factor in oral squamous cell carcinoma-a single-institutional experience from a developing country. J Oral Maxillofac Pathol. 25:322–326. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lichterman JN and Reddy SM: Mast cells: A new frontier for cancer immunotherapy. Cells. 10:12702021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cai XJ, Peng CR, Zhang JY, Li XF, Wang X, Han Y, Zhang HY, Peng X and Li TJ: Mast cell infiltration and subtype promote malignant transformation of oral precancer and progression of oral cancer. Cancer Res Commun. 4:2203–2214. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Teófilo CR, Ferreira AEC Junior, Batista AC, Fechini Jamacaru FV, Sousa FB, Lima Mota MR, Silva MFE, Barros Silva PG and Alves APNN: Mast cells and blood vessels profile in oral carcinogenesis: An immunohistochemistry study. Asian Pac J Cancer Prev. 21:1097–1102. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hasan NR, Dehuri P, Jena A and Kanungo S: A correlation of serum histamine and mast cell count with the established prognosticators in oral cancer. J Microsc Ultrastruct. 11:97–102. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hemmerlein B, Reinhardt L, Wiechens B, Khromov T, Schliephake H and Brockmeyer P: Is CCL2 an important mediator of mast cell-tumor cell interactions in oral squamous cell carcinoma? Int J Mol Sci. 24:36412023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tzorakoleftheraki SE and Koletsa T: The complex role of mast cells in head and neck squamous cell carcinoma: A systematic review. Medicina (Kaunas). 60:11732024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Shrestha A, Keshwar S and Raut T: Evaluation of mast cells in oral potentially malignant disorders and oral squamous cell carcinoma. Int J Dent. 2021:56095632021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kamal R, Dahiya P, Goyal N, Kumar M, Sharma N and Saini HR: Mast cells and oral pathologies: A review. J Nat Sci Biol Med. 6:35–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Salem A and Salo T: Nothing to sneeze at: Histamine and histamine receptors in oral carcinogenesis. Oral Dis. 27:1090–1096. 2021. View Article : Google Scholar
|
|
82
|
Oliveira-Neto HH, Leite AF, Costa NL, Alencar RC, Lara VS, Silva TA, Leles CR, Mendonça FE and Batista AC: Decrease in mast cells in oral squamous cell carcinoma: Possible failure in the migration of these cells. Oral Oncol. 43:484–490. 2007. View Article : Google Scholar
|
|
83
|
Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S and Wanachantararak S: Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med. 32:195–199. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Michailidou EZ, Markopoulos AK and Antoniades DZ: Mast cells and angiogenesis in oral malignant and premalignant lesions. Open Dent J. 2:126–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Salem A, Almahmoudi R, Listyarifah D, Siponen M, Maaninka K, Al-Samadi A, Salo T and Eklund KK: Histamine H4 receptor signalling in tongue cancer and its potential role in oral carcinogenesis-a short report. Cell Oncol (Dordr). 40:621–630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gaje PN, Amalia Ceausu R, Jitariu A, Stratul SI, Rusu LC, Popovici RA and Raica M: Mast cells: Key players in the shadow in oral inflammation and in squamous cell carcinoma of the oral cavity. Biomed Res Int. 2016:92350802016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ansari FM, Asif M, Kiani MN, Ara N, Ishaque M and Khan R: Evaluation of mast cell density using CD117 antibody and microvessel density using CD34 antibody in different grades of oral squamous cell carcinoma. Asian Pac J Cancer Prev. 21:3533–3538. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kim JY, Moon S and Kim D: Oral squamous cell carcinoma-derived ANGPTL3 induces cancer associated fibroblastic phenotypes in surrounding fibroblasts. Asian Pac J Cancer Prev. 23:4315–4322. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ren X, Li L, Wu J, Lin K, He Y and Bian L: PDGF-BB regulates the transformation of fibroblasts into cancer-associated fibroblasts via the lncRNA LURAP1L-AS1/LURAP1L/IKK/IκB/NF-κB signaling pathway. Oncol Lett. 22:5372021. View Article : Google Scholar
|
|
90
|
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al: A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 20:174–186. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bienkowska KJ, Hanley CJ and Thomas GJ: Cancer-associated fibroblasts in oral cancer: A current perspective on function and potential for therapeutic targeting. Front Oral Health. 2:6863372021. View Article : Google Scholar
|
|
92
|
Chaudhary M, Gadbail AR, Vidhale G, Mankar Gadbail MP, Gondivkar SM, Gawande M and Patil S: Comparison of myofibroblasts expression in oral squamous cell carcinoma, verrucous carcinoma, high risk epithelial dysplasia, low risk epithelial dysplasia and normal oral mucosa. Head Neck Pathol. 6:305–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang X and Hwang YS: Cancer-associated fibroblast stimulates cancer cell invasion in an interleukin-1 receptor (IL-1R)-dependent manner. Oncol Lett. 18:4645–4650. 2019.PubMed/NCBI
|
|
94
|
Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T and Coletta RD: Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol. 47:840–846. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, et al: HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15:3740–3750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang Y, Jing Y, Ding L, Zhang X, Song Y, Chen S, Zhao X, Huang X, Pu Y, Wang Z, et al: Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway. J Exp Clin Cancer Res. 38:2742019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ferreira Mendes JM, de Faro Valverde L, Torres Andion Vidal M, Paredes BD, Coelho P, Allahdadi KJ, Coletta RD, Souza BSF and Rocha CAG: Effects of IGF-1 on proliferation, angiogenesis, tumor stem cell populations and activation of AKT and hedgehog pathways in oral squamous cell carcinoma. Int J Mol Sci. 21:64872020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yang W, Zhang S, Li T, Zhou Z and Pan J: Single-cell analysis reveals that cancer-associated fibroblasts stimulate oral squamous cell carcinoma invasion via the TGF-β/Smad pathway. Acta Biochim Biophys Sin (Shanghai). 55:262–273. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, et al: The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 8:3984–4001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang Z, Gao Z, Rajthala S, Sapkota D, Dongre H, Parajuli H, Suliman S, Das R, Li L, Bindoff LA, et al: Metabolic reprogramming of normal oral fibroblasts correlated with increased glycolytic metabolism of oral squamous cell carcinoma and precedes their activation into carcinoma associated fibroblasts. Cell Mol Life Sci. 77:1115–1133. 2020. View Article : Google Scholar
|
|
101
|
Li X, Jiang E, Zhao H, Chen Y, Xu Y, Feng C, Li J and Shang Z: Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: Role of PGC-1α/PFKFB3 axis. Br J Cancer. 127:449–461. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Liu P, Wang Y, Li X, Liu Z, Sun Y, Liu H, Shao Z, Jiang E, Zhou X and Shang Z: Enhanced lipid biosynthesis in oral squamous cell carcinoma cancer-associated fibroblasts contributes to tumor progression: Role of IL8/AKT/p-ACLY axis. Cancer Sci. 115:1433–1445. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang Z, Tao D, Zhang P, Liu X, Zhang Y, Cheng J, Yuan H, Liu L and Jiang H: Hyaluronan synthase 2 expressed by cancer-associated fibroblasts promotes oral cancer invasion. J Exp Clin Cancer Res. 35:1812016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Matos LL, Menderico GM Junior, Theodoro TR, Pasini FS, Ishikawa MM, Ribeiro AAB, de Mello ES, Pinhal MADS, Moyses RA, Kulcsar MAV, et al: Cancer-associated fibroblast regulation by microRNAs promotes invasion of oral squamous cell carcinoma. Oral Oncol. 110:1049092020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhang JY, Zhu WW, Wang MY, Zhai RD, Wang Q, Shen WL and Liu LK: Cancer-associated fibroblasts promote oral squamous cell carcinoma progression through LOX-mediated matrix stiffness. J Transl Med. 19:5132021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Liu X, Li J, Yang X, Li X, Kong J, Qi D, Zhang F, Sun B, Liu Y and Liu T: Carcinoma-associated fibroblast-derived lysyl oxidase-rich extracellular vesicles mediate collagen crosslinking and promote epithelial-mesenchymal transition via p-FAK/p-paxillin/YAP signaling. Int J Oral Sci. 15:322023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Elmusrati AA, Pilborough AE, Khurram SA and Lambert DW: Cancer-associated fibroblasts promote bone invasion in oral squamous cell carcinoma. Br J Cancer. 117:867–875. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT and Wight TN: Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 31:90–100. 2012. View Article : Google Scholar
|
|
109
|
Takahashi H, Sakakura K, Kudo T, Toyoda M, Kaira K, Oyama T and Chikamatsu K: Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget. 8:8633–8647. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hu S, Lu H, Xie W, Wang D, Shan Z, Xing X, Wang XM, Fang J, Dong W, Dai W, et al: TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. J Clin Invest. 132:e1576492022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Peltanova B, Liskova M, Gumulec J, Raudenska M, Polanska HH, Vaculovic T, Kalfert D, Grega M, Plzak J, Betka J and Masarik M: Sensitivity to cisplatin in head and neck cancer cells is significantly affected by patient-derived cancer-associated fibroblasts. Int J Mol Sci. 22:19122021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Tao L, Huang G, Wang R, Pan Y, He Z, Chu X, Song H and Chen L: Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Sci Rep. 6:384082016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Kang SH, Oh SY, Lee KY, Lee HJ, Kim MS, Kwon TG, Kim JW, Lee ST, Choi SY and Hong SH: Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3p. Theranostics. 14:460–479. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Graizel D, Zlotogorski-Hurvitz A, Tsesis I, Rosen E, Kedem R and Vered M: Oral cancer-associated fibroblasts predict poor survival: Systematic review and meta-analysis. Oral Dis. 26:733–744. 2020. View Article : Google Scholar
|
|
115
|
Li Y, Ma Z, Li W, Xu X, Shen P, Zhang SE, Cheng B and Xia J: PDPN+ CAFs facilitate the motility of OSCC cells by inhibiting ferroptosis via transferring exosomal lncRNA FTX. Cell Death Dis. 14:7592023. View Article : Google Scholar
|
|
116
|
Maman S and Witz IP: A history of exploring cancer in context. Nat Rev Cancer. 18:359–376. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH and Sautès-Fridman C: The clinical role of the TME in solid cancer. Br J Cancer. 120:45–53. 2019. View Article : Google Scholar :
|
|
118
|
Harding FA, McArthur JG, Gross JA, Raulet DH and Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356:607–609. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA and Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:541–547. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Ferris RL: Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 33:3293–3304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Hu Y, Lin L, Chen J, Hao K, Zhang S, Guo X, Guo Z, Tian H and Chen X: Highly enhanced antitumor immunity by a three-barreled strategy of the l-arginine-promoted nanovaccine and gene-mediated PD-L1 blockade. ACS Appl Mater Interfaces. 12:41127–41137. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Qiao XW, Jiang J, Pang X, Huang MC, Tang YJ, Liang XH and Tang YL: The evolving landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol. 11:17212020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, et al: PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathol Res Pract. 226:1536052021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Girolami I, Pantanowitz L, Barberis M, Paolino G, Brunelli M, Vigliar E, Munari E, Satturwar S, Troncone G and Eccher A: Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma. J Oral Pathol Med. 50:864–873. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Almangush A, Leivo I and Mäkitie AA: Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: Time to take notice. Acta Otolaryngol. 140:246–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Cramer JD, Burtness B and Ferris RL: Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol. 99:1044602019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Moskovitz JM and Ferris RL: Tumor immunology and immunotherapy for head and neck squamous cell carcinoma. J Dent Res. 97:622–626. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, et al: Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 107:142–152. 2019. View Article : Google Scholar
|
|
131
|
Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA and Walker J: Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 11:952016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al: Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 34:3838–3845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, et al: Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 41:790–802. 2023. View Article : Google Scholar :
|
|
136
|
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, et al: Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-Year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, et al: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial. Clin Cancer Res. 26:5140–5152. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, et al: Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 28:1345–1352. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Uppaluri R, Lee NY, Westra W, Cohen EE, Haddad RI, Temam S, Le Tourneau C, Chernock R, Safina S, Klochikhin A, et al: KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. J Clin Oncol. 37(15 Suppl): TPS60902019. View Article : Google Scholar
|
|
140
|
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, et al: Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 384:1191–1203. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Wong W, Cracchiolo JR, Riaz N, Ganly I, Sherman EJ, Ho AL, Morris L, Ghossein RA, Haque S, Hung KW, et al: Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC). J Clin Oncol. 41(16 Suppl): S60192023. View Article : Google Scholar
|
|
143
|
Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H, Li Y, Su Y, Lu L, Chen L, et al: Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: A pilot phase II trial. Nat Commun. 15:21772024. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Yu Y and Lee NY: JAVELIN Head and Neck 100: A Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. Future Oncol. 15:687–694. 2019. View Article : Google Scholar
|
|
145
|
Wong DJ, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, et al: Abstract CT009: IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Cancer Res. 84(7 Suppl): CT0092024. View Article : Google Scholar
|
|
146
|
Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang SC, Koguchi Y, Bifulco CB, Bernard B, Leidner RS, et al: Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun. 12:10472021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Shrikant P, Khoruts A and Mescher MF: CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity. 11:483–493. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Lee WS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, Yeo SP, Soh MK, Chan EHL, Tan LK, et al: Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. Mol Cancer Ther. 20:1702–1712. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A, et al: Preclinical development of the anti-LAG-3 antibody REGN3767: Characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-knockin mice. Mol Cancer Ther. 18:2051–2062. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Huang J, Barbera L, Brouwers M, Browman G and Mackillop WJ: Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 21:555–563. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Maeda S, Murakami K, Inoue A, Yonezawa T and Matsuki N: CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer. Cancer Immunol Res. 7:1175–1187. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K and McHugh JB; INSPIRE Trial Clinical Investigators: Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncol. 111:1049282020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Jiang T, Zhou C and Ren S: Role of IL-2 in cancer immunotherapy. Oncoimmunology. 5:e11634622016. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Tarhini AA, Gogas H and Kirkwood JM: IFN-α in the treatment of melanoma. J Immunol. 189:3789–3793. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Chien MH, Hsin CH, Chou LS, Chung TT, Lin CH, Weng MS, Chou MY, Chen MK and Yang SF: Interleukin-23 receptor polymorphism as a risk factor for oral cancer susceptibility. Head Neck. 34:551–556. 2012. View Article : Google Scholar
|
|
156
|
Tian S, Jiang C, Liu X, Xu S, Zhang Z, Chen H, Zhang Y, Liu Y and Ma D: Hypermethylation of IFN-γ in oral cancer tissues. Clin Oral Investig. 21:2535–2542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Kong AH, Hesselink MSK, Aguilera B, Adkins D, Even C, Fayette J, Muzaffar J, Visscher S, Melief CJM and Hooftman LW: Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy. J Clin Oncol. 41(16 Suppl): S60282023. View Article : Google Scholar
|
